Share

 
Facebook
 
Linkedin
 
Website
 
Email
Fall 2025
Hi!

It continues to be quite a busy year for Tunnell.  We recently sponsored MassBio's Align Summit, participated in BIO's Annual Conference and will attend Pennsylvania Biotech Center's upcoming Regional Conference. We've enjoyed reconnecting with old friends and appreciated making new ones.  And, of course, we continue to provide our clients with hands-on expertise and continued support. 

I hope you enjoy our latest newsletter.  
Please do take time to relax and enjoy the crisp fall weather!

Maryann Gallivan
President and CEO
maryann.gallivan@tunnellconsulting.com
Who We Are
Joshua B. Fine, DVM, MPH, DACVPM, PMP
Josh, who has been with Tunnell since 2013, is a Principal and Senior Scientific Advisor. He provides direct technical support to federal and academic clientele as a program manager and as a source of subject matter expertise in topics ranging from public health, infectious disease, veterinary medical countermeasure development and biosafety. He has been instrumental in supporting Tunnell’s initiatives at the Food and Drug Administration (FDA) and with programs at the Department of Health and Human Services (HHS). While participating in the Laboratory Testing and Diagnostics Working Group, Office of the Assistant Secretary for Health (OASH), Josh supported the HHS-Federal Emergency Management Agency (FEMA) interagency response under the direction of the White House Coronavirus Task Force and OASH. He also co-authored the first HHS COVID-19 Strategic Testing Plan, a report to Congress submitted in May 2020, prepared in response to the Paycheck Protection Program and Health Care Enhancement Act, P.L. 116-139.

In his limited spare time Josh dotes on Miller, his Great Pyrenees/Chow mix, and travels the world catching exotic fish with his self-designed flies. In fact, one of them, the Montauk Monster, is even sold by Orvis.

What We're Saying...Our Latest Thought Leadership

De-Risking U.S. Market Entry of Early Stage Therapeutics
Early-stage therapeutic development can falter without proper medical and scientific data coupled with complete documentation elucidating the path from preclinical to FIH. Good science does not always get to the clinic, as documentation and repeatability are paramount to the therapeutic journey. By aligning preclinical research, translational medicine, and clinical development with regulatory expectations; differentiating therapeutic assets early and on an ongoing basis; and leveraging external expertise, companies can avoid costly missteps and possibly accelerate their entry into the highly competitive U.S. market.
By Melissa Allensworth


Where We've Been, Where We're Going...
Aug. 14th--Meet the Leaders
Tunnell attended this event.

Sept. 25th & 26th--Life Sciences Future
Tunnell sponsored this event and Tunnell Principal, Scott Myers, sat on the panel of experts.


Sept. 4th--MassBio Forum: Biotech’s 2025 Midyear Check-Up
Tunnell CEO Maryann Gallivan was a moderator of this event,


Oct. 7th--Align Summit
Tunnell sponsored this event.
Sept. 18th Boston Biotech Investor Day
Tunnell was a sponsor of this event
Aug. 11th--Fore One Purpose
Tunnell sponsored this charitable golf tournament.
Sept. 18th & 19th-- Contract Pharma--2025 Contracting and Outsourcing Conference
Tunnell Principal, Lisa Cozza, presented on Navigating Complex Partnerships: The Role of the Alliance Manager.
Oct. 16th--BPD Roundtable Discussion
Tunnell Principal, Lisa Cozza, presented on Building an Agile Yet Reliable Operations Team.
Oct. 9th--Tunnell Principal, Melissa Allensworth, presented on, Moving From Academia to Industry in Biotech.


June 5th--Entrepreneur Spotlight  
Tunnell was a sponsor of this event.

Nov. 13th--Regional Conference
Tunnell will attend this event




We Hope To See You At Upcoming Events!

Check out Tunnell's sister companies, Turesol Staffing Solutions and Tunnell Government Services!

Email Marketing by ActiveCampaign